IGF-1 LR3
Potent growth-factor analog; High-risk gray-market use
Brief Overview: IGF-1 LR3 is a modified insulin-like growth factor designed to last longer and bind IGF-binding proteins differently than native IGF-1. It is discussed for muscle growth and recovery, but the biology also overlaps with glucose lowering and cell-growth signaling. Evidence lens: This is not a beginner compound. Human therapeutic use of growth factors requires careful indication and monitoring. Community claims about hypertrophy are not the same as controlled safety data. How to read this: Once you're past the basics, focus on hypoglycemia risk, cancer-theory concerns, organ/tissue growth signaling, edema, neuropathic symptoms, and the fact that a longer half-life can mean more prolonged adverse effects.
- IGF-1 LR3 is a modified IGF-1 analog with altered binding characteristics and prolonged activity relative to native IGF-1.
- IGF-1 LR3 is a modified long-acting IGF-1 analog used in research/bodybuilding contexts, not standard mecasermin therapy. LR3 modification changes binding-protein interaction and risk profile.
- It promotes anabolic and glucose-disposal signaling through IGF-related pathways.
- It activates IGF-1 receptor signaling involved in growth, glucose disposal, and anabolic pathways. That same biology creates hypoglycemia and growth-signaling concerns. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Bodybuilding claims and animal data are not approved therapeutic evidence.
- Approved recombinant IGF-1 products have specific indications and labels that do not validate gray-market LR3 use.
- Clinical evidence for LR3 as a performance or physique peptide is not established. Extrapolating from IGF-1 biology or mecasermin does not validate LR3 research-market use. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Conservative Anabolic Phase [Research/Experimental]; Route: Subcutaneous (SC); Dose: 20 mcg – 40 mcg; Frequency: Once Daily; Timing: Post-Workout (with Carbs); Duration: 4 weeks ON / 4 weeks OFF; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Advanced Recovery Protocol [Research/Experimental]; Route: Subcutaneous (SC); Dose: 50 mcg – 80 mcg; Frequency: Once Daily; Timing: Post-Workout or Morning; Duration: 4 weeks ON / 4 weeks OFF; Source also contains wrapped text '6 weeks ON / 6 weeks OFF'; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Dosing claims are uncertain because potency, route, concentration, and acidic reconstitution practices vary. It should not be casually blended with neutral peptides. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
IGF-1 LR3 has a dramatically extended half-life (~20 to 30 hours) compared to native IGF-1 (~10 to 12 minutes free / 15 hours bound) due to its low affinity for IGFBPs. This allows once-daily subcutaneous dosing while maintaining sustained receptor activation. Tissue distribution is systemic, with peak skeletal-muscle exposure within 4 to 6 hours of injection.
- Time until steady state: about 4-6 days if that estimate is used.
- Half-life basis: Commonly reported 20-30 hours, but not from an FDA-approved human label. Because IGF-1 LR3 is a potent growth-factor analog, this estimate is not a validated human dosing model.
- Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
- LR3 is designed for longer activity than native IGF-1, but public human PK for community products is weak. Effects on glucose can be clinically important even when subjective effects are subtle. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Growth Hormone (HGH): HGH signals the liver to produce IGF-1. Stacking exogenous IGF-1 LR3 with HGH creates a “saturated” environment for maximum cellular growth.
- Testosterone: IGF-1 LR3 enhances the androgen receptor sensitivity, making a given dose of testosterone more effective at the cellular level.
- Stacking with insulin, GH, GH secretagogues, or anabolic agents increases hypoglycemia and growth-signal concerns. Avoid same-vial mixing, especially with acidic-solvent preparations. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Hypoglycemia: Because it mimics insulin, a sudden drop in blood sugar is the most immediate risk.
- Organ Growth (Visceromegaly): Long-term, high-dose abuse can theoretically lead to the growth of non-skeletal muscle tissues (intestines, heart).
- Mitogenic Risk: Since it promotes cell division, it should never be used by anyone with active cancer or a history of malignancies, as it may accelerate the growth of existing tumors. “Peptide Bloat”: Temporary water retention or “puffy” joints.
- Major practical risks include hypoglycemia, edema, jaw/soft-tissue symptoms, neuropathy-like symptoms, and theoretical tumor-growth concerns. This is not a beginner peptide. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Fasting Blood Glucose: To ensure the peptide isn’t causing metabolic stress.
- Serum IGF-1 Levels: To track the total systemic load.
- Body Composition (DEXA): To distinguish between true hyperplasia and mere water retention.
- Monitor fasting and post-dose glucose, hypoglycemia symptoms, IGF-1 context, edema, blood pressure, and any history of malignancy. Keep carbohydrate intake and timing documented in research contexts. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: Not approved for human use; Strictly for research and laboratory purposes.
- WADA: Strictly Banned in all sports (S2 Category). It is highly detectable via modern mass spectrometry (LC-MS).
- Clinical Outlook: While not currently in mainstream medical use, it remains a primary tool in research for muscle wasting diseases and regenerative medicine.
- IGF-1 LR3 is not an FDA-approved therapeutic product. It may also trigger anti-doping issues and is high-risk in sports contexts. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.